[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"remote-patient-monitoring\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:remote-patient-monitoring":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,74,109,136,170],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100637770","changing-outpatient-diabetes-care-with-remote-patient-monitoring-a-real-world-evidence-study-with-pre-post-comparison-100637770",false,"NCT07617519","Changing Outpatient Diabetes Care With Remote-Patient-Monitoring: A Real World Evidence Study With Pre-Post Comparison","Inclusion Criteria:\n\n* All people with active clinical care at SDCC during each period and thereby included in the RPM.\n\nExclusion Criteria:\n\n* All people without active clinical care at SDCC during each period.","ALL",{"count":17,"type":18},12000,"ESTIMATED","OBSERVATIONAL","The goal of this observational pre-post study is to evaluate a remote-patient-monitoring-system (RPM-system) integrated within an electronic health record (EHR) system in a real world cohort of approximately 12.000 people with diabetes in an outpatient care setting. The main question it aims to answer is:\n\nWhether glycemic outcomes following integration of the RPM system into the EHR over a two-year period are non-inferior compared with outcomes observed prior to an ambulatory care restructuring (including a prototype of the RPM-system) in October 2024.\n\nParticipants are included in the RPM-system as part of their regular medical care for diabetes.",[22,23,24,25,26,27],"Diabetes","Diabetes Care","Diabetes Type 1","Diabetes Type 2","Remote Patient Monitoring","Digital Health","NOT_YET_RECRUITING","2026-06-22",{"date":31,"type":32},"2026-06-25","ACTUAL",{"date":34,"type":18},"2026-06",{"date":36,"type":18},"2028-07",{"name":38,"class":39},"Steno Diabetes Center Copenhagen","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":40},"100641853","bloodtrackr-usability-and-concordance-study-bucs-evaluating-a-smart-home-based-blood-collection-platform-for-remote-monitoring-in-rheumatoid-arthritis-100641853","NCT07660029","BloodTrackR Usability and Concordance Study (BUCS): Evaluating a Smart Home-Based Blood Collection Platform for Remote Monitoring in Rheumatoid Arthritis","BloodTrackR Usability and Concordance Study (BUCS)","BUCS","Inclusion Criteria:\n\n* Individuals living with rheumatoid arthritis, who attend community groups or rheumatoid arthritis charity groups\n* Aged 18 years or older\n* Able to understand written and spoken English\n* Individuals who have the capacity to consent\n* Access to WiFi and a smartphone\u002Ftablet\n\nExclusion Criteria:\n\n* Participants \\\u003C18years\n* Participants taking antibiotics\u002Fantivirals\n* No access to WiFi or a smartphone\u002Ftablet","18 Years",{"count":51,"type":18},20,"The BloodTrackR Usability and Concordance Study (BUCS) is evaluating a novel home-based blood collection device and companion mobile application for people with rheumatoid arthritis. Participants will use the BloodTrackR device to collect a finger-prick blood sample at home and complete symptom assessments through the app.\n\nThe study will assess how easy the device and app are to use, whether participants can successfully collect high-quality blood samples outside of a healthcare setting, and how closely the results compare with standard venous blood samples collected by a phlebotomist. Findings will help determine the potential of BloodTrackR to support remote monitoring and reduce reliance on NHS phlebotomy services.",[54,26],"Rheumatoid Arthritis (RA)",[56,57,26,58,59,60,61,62,27,63,64],"Rheumatoid Arthritis","Home Blood Collection","BloodTrackR","Blood Microsampling","CRP","Usability Study","Concordance Study","Mobile Health","Remote Monitoring","RECRUITING","2026-06-19",{"date":68,"type":32},"2026-06-24",{"date":34,"type":18},{"date":71,"type":18},"2026-12",{"name":73,"class":39},"University of Ulster",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":85,"conditions":86,"keywords":93,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":40},"100593355","fitbit-and-ai-chatbot-in-sedentary-primary-care-patients-with-t2d-100593355","NCT07005362","Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D","Feasibility of Use of Fitbit, Brief DSMES, and Targeted Text Messaging in Sedentary Adults With Type 2 Diabetes in Primary Care Settings","FIT T2D","Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes per investigator discretion\n* No more than 20% of the sample will have A1c \\\u003C 7.5% (confirmed by medical record review or an A1c completed within 3 months of the screening visit)\n* Age ≥18 years and ≤ 80 years\n* Does not meet ADA guidelines for physical activity (\\\u003C 150 minutes of aerobic exercise per week defined as any activity where the participant can talk but not sing)\n* Has a smartphone compatible with a Fitbit\n\nExclusion Criteria:\n\n* Completing more than 60 minutes of moderate to vigorous activity per week defined as activity where you cannot sing (moderate) or can't say more than a few words without gasping for breath (vigorous)(14)\n* Any medical condition which, in the opinion of the investigator, would put the participant at an unacceptable safety risk, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, and\u002For eating disorders.\n* Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the previous 12- months\n* Any planned surgery during the study which could be considered major in the opinion of the investigator\n* Blood disorder or dyscrasia within 3 months before screening, or the use of hydroxyurea, which, in the investigator's opinion, could interfere with the determination of HbA1c\n* Has taken oral or injectable steroids within the past 8 weeks or plans to take oral or injectable steroids during the study, as they may interfere with the determination of HbA1c.\n* Planning to move from Colorado within 3 months\n* Current Pregnancy or planning on pregnancy in the next 3 months\n* Unable to safely comply with study procedures and reporting requirements (e.g. impairment of vision that impacts ability to see FitBit, impaired memory)\n* Unable to speak English as this is a small feasibility study that does not have the resources to adapt the intervention for Spanish\n* Current participation in another diabetes-related clinical trial","80 Years",{"count":84,"type":18},36,"The goal of this observational study is to evaluate the feasibility and acceptability of a 12-week intervention utilizing a Fitbit and artificial intelligence (AI)-delivered diabetes self-management education and support (DSMES) with tailored text messages.\n\nThe main question it aims to answer is:\n\nDoes providing a wearable fitness and activity tracker plus AI-tailored and DSMES improve clinical outcomes for patients with type 2 diabetes?\n\nParticipants will complete a baseline visit, wear a Fitbit and answer text messages for 12-weeks, and complete by a final visit.",[87,88,89,90,91,26,92],"Type 2 Diabetes","Type 2 Diabetes Mellitus (T2DM)","T2DM (Type 2 Diabetes Mellitus)","T2D","T2DM","Artificial Intelegence",[94,95,96,97,98,99],"type 2 diabetes","artificial intelligence","fitbit","primary care","remote patient monitoring","physical activity","2026-05-15",{"date":102,"type":32},"2026-05-19",{"date":104,"type":32},"2025-09-03",{"date":106,"type":18},"2026-08-30",{"name":108,"class":39},"University of Colorado, Denver",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":116,"minAge":49,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":40},"100579295","remote-fetal-monitoring-in-high-risk-pregnancies-100579295","NCT06822439","Remote Fetal Monitoring in High Risk Pregnancies","Investigating the Acceptability and Feasibility of Remote Fetal Monitoring in a High Risk Obstetric Population","Inclusion Criteria:\n\n* Intrauterine pregnancy greater than 32 weeks gestation\n* Recommended for at least once weekly antenatal fetal testing by their obstetrician\n* English-speaking\n\nExclusion Criteria:\n\n* Under age 18 years of old\n* Non-english speaking","FEMALE",{"count":118,"type":18},50,"Antenatal nonstress tests (NSTs) are performed to assess fetal health and are used as a cost-effective test that can be widely administered. However, an NST is operator-dependent due to the nature of Doppler ultrasound and is primarily performed in a clinic and hospital setting.\n\nThe ability to conduct a clinically valuable test at home would address access to care issues faced by numerous women in the United States and reduce the workload on healthcare clinicians facing a shortage of human resources.\n\nThis pilot study aims to assess the feasibility and acceptability of home NST monitoring in order to determine whether femomTM could be utilized as an adjunct to routine prenatal care.\n\nPatients with high risk pregnancies who are recommended to undergo at least once weekly at 32 weeks testing by the obstetrician will be recruited for participation in this study. Participants will be asked to perform three 30 minute monitoring sessions weekly starting at 32 weeks for 6 weeks.",[121,26,22,122],"High Risk Pregnancy","Hypertension",[124,125,126],"Pregnancy","Non invasive testing","Remote patient monitoring","2026-03-06",{"date":129,"type":32},"2026-03-09",{"date":131,"type":32},"2025-05-01",{"date":133,"type":18},"2027-01-01",{"name":135,"class":39},"Beth Israel Deaconess Medical Center",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":146,"phases":147,"briefSummary":149,"conditions":150,"keywords":155,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":40},"100601102","phase-4-antibiotics-for-kidney-transplant-recipients-100601102","NCT07106125","Antibiotics for Kidney Transplant Recipients","Trial of Antibiotic Strategies for Kidney Transplant Recipients","TASK","Inclusion Criteria:\n\n* Must be able to take capsules orally\n* Kidney transplant performed at a UCSF facility within the last 6 months\n* Most recent glomerular filtration rate (GFR) \\>30 mL\u002Fmin\u002F1.73 m2\n* Tolerated initial 6 months of post-transplant TMP-SMX (defined as no intentional periods of TMP-SMX cessation in first 6 months after transplant due to hyperkalemia, allergic reaction, or unexpected\u002Fexcessive neutropenia)\n* Considered \"high risk for UTI\" after kidney transplant, as defined by one or more of the following: (1) Congenital anomaly of kidney\u002Furinary tract as kidney failure etiology, (2) Diagnosis of neurogenic bladder and\u002For use of clean intermittent catheterization and\u002For nightly continuous urinary drainage, (3) Diabetes mellitus (diagnosed either prior to or new-onset after transplant), (4) History of recurrent UTIs as diagnosed by a provider prior to transplant, (5) Occurrence of any UTI in first 6 months after transplant, (6) Delayed graft function (defined as need for dialysis within 7 days of transplant)\n\nExclusion Criteria:\n\n* History of intolerance or allergy to trimethoprim (TMP) and\u002For sulfamethoxazole (SMX)\n* History of UTI due to a TMP-SMX-resistant organism in the first 6 months after transplant\n* Moderate or severe neutropenia (absolute neutrophil count \\\u003C1,000 cells\u002FμL) on most recent bloodwork available at the time of recruitment\n* Uncontrolled hyperkalemia (serum potassium ≥5.0 mEq\u002FL) on most recent bloodwork available at the time of recruitment\n* Provider-determined\u002Fdocumented need for either continuation or discontinuation of TMP-SMX prophylaxis that would preclude the patient's randomization\n* Current pregnancy\n* Incarcerated individuals\u002Fprisoners\n* Inability to provide informed consent or assent, and no legally authorized representative available","29 Years",{"count":118,"type":18},"INTERVENTIONAL",[148],"PHASE4","The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months.\n\nThe main questions this study is asking are:\n\n* Does TMP-SMX lower the number of UTIs in the first year after transplant?\n* What side effects or problems do participants have while taking TMP-SMX?\n\nResearchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs.\n\nParticipants will:\n\n* Take either TMP-SMX or a placebo pill by mouth every day for 6 months\n* Have three visits to touch base with the study team about any issues\n* Complete short monthly online surveys about any symptoms or side effects\n* Share blood and urine test results from their regular transplant clinic visits",[151,152,153,26,154],"Kidney Transplant","Urinary Tract Infection(UTI)","Antibiotic Prophylaxis","Feasibility Pilot Study",[156,157,158,159,160],"kidney transplant","UTI prevention","antibiotic prophylaxis","decentralized trial","remote clinical trial","2025-10-29",{"date":163,"type":32},"2025-10-31",{"date":165,"type":18},"2026-11",{"date":167,"type":18},"2029-01",{"name":169,"class":39},"University of California, San Francisco",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":146,"phases":178,"briefSummary":180,"conditions":181,"keywords":184,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":40},"100573917","remote-temperature-monitoring-of-patients-at-risk-for-developing-fever-100573917","NCT06752512","Remote Temperature Monitoring of Patients At Risk for Developing Fever","Inclusion Criteria:\n\n* Subject is at risk of a fever post discharge.\n* Subject is ≥ 18 years or older.\n* Subject has an iOS or Android phone, or is able to operate an AION provided smartphone device.\n* Subject is willing to install the TempShield app on his\u002Fher phone.\n* Subject is willing to allow AION to send text reminders to take temperature or complete surveys.\n* Subject is willing to take an oral temperature as directed by their care plan.\n* Subject is willing to configure the phone to ensure these notifications are delivered, even when phone is in a \"no notification\" mode.\n* Subject or subject caretaker is able and willing to complete subject surveys.\n* Subject is willing and able to provide written informed consent in English.\n* Subject is willing and able to comply with all program procedures, requirements, assessments, visits, and complete questionnaires.\n* English speakers\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Subjects with a history of Medical Adhesive-Related Skin Injury (MARSI)\n* Subjects with no available placement that avoids open wounds or traumatized skin (burns. Blisters. Etc.)\n* Non-English speakers: The mobile application is only currently available in English. Future development will include other languages.\n* Subjects receiving prophylactics that could induce fever.\n* Subjects with a silicon allergy\n* Subject does not have iOS or Android phone, and is unable to operate an AION provided smartphone device.\n* Subjects who are not willing to take an oral temperature per their care plan.",{"count":177,"type":18},150,[179],"NA","The purpose of this program is to evaluate remote temperature monitoring in cancer patients at risk of fever and infection due to chemotherapy treatment. The main questions it aims to answer are:\n\n* does remote temperature monitoring reduce the number of days spent inpatient\n* what out-of-pocket cost can a patient expect to incur for participating in remote temperature monitoring\n* the number of billable CPT codes that will be generated by providing remote temperature monitoring\n\nResearchers will compare compliant and non-compliant patients to assess if compliance with remote temperature monitoring is associated with a decrease in the number of days spent inpatient.\n\nPatients will\n\n* wear the thermometer for the duration of their participation in the study\n* have their temperature monitored continuously\n* receive alerts on their phone when their temperature exceeds a threshold for a sustained duration, configurable by their physician\n* respond to texts or calls from remote monitors when an alert is triggered",[182,183,26],"Fever","Cancer",[185,186,187,188,189,190,191,192,98],"fever","infection","sepsis","cancer","chemotherapy","immunocompromised","temperature","wearable","2024-12-22",{"date":195,"type":32},"2024-12-30",{"date":197,"type":32},"2023-08-09",{"date":199,"type":18},"2025-01",{"name":201,"class":202},"AION Biosystems","INDUSTRY"]